Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Phase 1/2 Recruiting
20 enrolled
TPT CED rHGG
Phase 1 Recruiting
6 enrolled
AIM_3D
Recruiting
200 enrolled
PRIOR
Recruiting
462 enrolled
BUDPA
Phase NA Recruiting
236 enrolled
TAB
Phase 2 Recruiting
310 enrolled
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma
Phase 2 Recruiting
100 enrolled
Development of Pressure Sensor Based Dementia and Fall Prevention Program for Older Adults
Phase NA Recruiting
205 enrolled
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma
Phase 2 Recruiting
20 enrolled
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 Recruiting
35 enrolled
Odronextamab in Low Tumor Volume Advanced FL
Phase 2 Recruiting
35 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
20 enrolled
GLP-1/GCG Dual Agonist in Type 2 Diabetes With Early Dementia (LIGHT-COG Study)
Phase 3 Recruiting
420 enrolled
5HTP Regulation Of Asthma In Children
Phase 2 Recruiting
20 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
SCARF-1
Phase 2 Recruiting
40 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Phase 1 Recruiting
12 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
33 enrolled
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
Phase 3 Recruiting
375 enrolled
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Phase 1 Recruiting
27 enrolled
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Recruiting
200 enrolled
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Phase 2 Recruiting
49 enrolled
The PRE-VAIL Study
Phase NA Recruiting
259 enrolled
Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas
Phase 2 Recruiting
43 enrolled
Cognitive Screening Made Easy for PCPs - Administrative Supplement
Phase NA Recruiting
100 enrolled
MosuOSSHSR
Recruiting
25 enrolled
FTT PET/CT in Pancreatic Neuroendocrine Tumors
Phase 1 Recruiting
12 enrolled
FIL_MOZART
Phase 2 Recruiting
56 enrolled
Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma
Phase 2 Recruiting
30 enrolled
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Phase 1 Recruiting
20 enrolled
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1 Recruiting
36 enrolled
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Phase 2 Recruiting
152 enrolled
Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma
Phase 2 Recruiting
52 enrolled
FIL_FOLL-BIO
Recruiting
654 enrolled
FIL_GAZEBO
Phase 3 Recruiting
190 enrolled
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Phase 2 Recruiting
100 enrolled
CUB-HS2025
Recruiting
363 enrolled
PWD
Phase NA Recruiting
60 enrolled
PRALISS
Phase NA Recruiting
48 enrolled
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Phase 2 Recruiting
22 enrolled
REEF
Phase NA Recruiting
20 enrolled
Emapalumab Prevention of CAR-T Cell Associated Toxicities
Phase 2 Recruiting
28 enrolled
Long-term Follow-up Study of Patients Receiving CAR-T Cells
Recruiting
500 enrolled
Auto Stem Cell Transplant for Lymphoma Patients
Phase 2 Recruiting
150 enrolled